CRM vs DHR: Which Is the Better Buy?
Side-by-side comparison of Salesforce, Inc. and Danaher Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-10.
Salesforce, Inc. · Technology
$169.52
+45.0% upside to fair value
Grade A
High Quality
VS
Danaher Corporation · Healthcare
$195.98
+7.9% upside to fair value
Grade B
High Quality
QuantHub Verdict
CRM has more upside to fair value
(+45.0%).
CRM trades at a lower forward P/E
(19.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRM |
DHR |
| Current Price |
$169.52 |
$195.98 |
| Fair Value Estimate |
$245.80 |
$211.54 |
| Upside to Fair Value |
+45.0%
|
+7.9%
|
| Market Cap |
$138.8B |
$138.7B |
| Forward P/E |
19.6x
|
37.8x
|
| EV / EBITDA |
12.3x
|
22.8x
|
| Price / Sales |
3.2x
|
5.6x
|
| Price / FCF |
9.5x
|
26.2x
|
| Revenue Growth YoY |
+13.3%
|
+3.7%
|
| Gross Margin |
77.6%
|
60.7%
|
| Operating Margin |
21.9%
|
21.0%
|
| Return on Equity |
14.9%
|
7.1%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
10.56%
|
3.81%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Salesforce, Inc. is a leading provider of cloud-based software applications primarily focused on customer relationship management (CRM). The company exhibits high business quality with a durable competitive moat supported by strong gross margins of 77.6%, solid operating margin of 21.9%, and a robust return on equity of 14.9%. Recent quarterly revenue growth of 13.3% and earnings growth of 36.7% …
Danaher Corporation operates in the healthcare sector, specifically in medical diagnostics and research, delivering high-quality products with a durable competitive moat supported by strong margins and consistent earnings growth. The company trades at a trailing and forward P/E of 37.76, which is relatively high but justified by its stable revenue growth of 3.7% and earnings growth of 7.9% in the…
Accumulation Zones
| Metric |
CRM |
DHR |
| Zone Low |
$184.35 |
$158.66 |
| Zone High |
$208.93 |
$179.81 |
| In Buy Zone? |
Yes
|
No
|